Hydrocodone/Acetaminophen for Acute Pain Following Bunionectomy

Pain Clinical Trial

Official title:

A Randomized, Multicenter, Single-Blind Study Comparing Hydrocodone/Acetaminophen Extended Release 10/650, Morphine Extended Release, and Acetaminophen to Placebo in Subjects With Acute Pain Following Bunionectomy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01038609
• Other study ID #: M12-058
• Status: Completed
• Phase: Phase 2
• First received: December 22, 2009
• Last updated: March 10, 2014
• Start date: December 2009
• Est. completion date: May 2010

Study information

• Verified date: March 2014
• Source: AbbVie
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The primary purpose of this study was to evaluate analgesic efficacy and safety of hydrocodone/acetaminophen extended release compared to placebo in moderate to severe pain following primary unilateral first metatarsal bunionectomy.

Description:

The bunionectomy was performed under regional anesthesia and propofol sedation. Perioperative anesthesia was standardized for all participants. Upon completion of surgery, designated study personnel ensured continued eligibility per the selection criteria of the protocol.

After an appropriate period of time following bunionectomy, participants who had a pain intensity score of ≥ 40 mm on a 100 mm visual analog scale (VAS) and moderate or severe pain intensity per the categorical pain intensity scale were eligible for randomization, in equal numbers, into 1 of 5 treatment arms. In order to maintain the single-blind nature of the study, all participants were dosed with study drug (active and/or placebo) every 6 hours.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 250
• Est. completion date: May 2010
• Est. primary completion date: May 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Subjects who were in general good health, experiencing moderate to severe pain following bunionectomy surgery and who were willing to remain confined for approximately 4 days following surgery for study procedures.

Exclusion Criteria:

• Subjects who underwent Base wedge osteotomy and/or Long-Z hart bunionectomy procedures

• Allergic reaction to study medications

• Pregnant or breastfeeding females

• Clinically significant lab abnormalities at screening

• Positive hepatitis testing at screening

• Clinically significant or uncontrolled medical disorders or illness at screening

• Active malignancy or chemotherapy

• Any history of drug or alcohol abuse/addiction

• Known or suspected history of human immunodeficiency virus (HIV); requires treatment with monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs) or butyrophenones

• History of major depressive episode or major psychiatric disorder

• Current systemic corticosteroid therapy

• Inability to refrain from smoking during or alcohol during stay at investigative site

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Acute Pain
• Pain

Intervention

Drug:
• Hydrocodone/Acetaminophen Extended Release

• Acetaminophen

• Morphine Extended Release

• Placebo

Locations

Country	Name	City	State
United States	Site Reference ID/Investigator# 26302	Austin	Texas
United States	Site Reference ID/Investigator# 26223	Peoria	Arizona
United States	Site Reference ID/Investigator# 26303	San Marcos	Texas
United States	Site Reference ID/Investigator# 26304	West Jordan	Utah

Sponsors (1)

Lead Sponsor	Collaborator
AbbVie (prior sponsor, Abbott)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sum of Pain Intensity Difference (SPID) Using the Pain Intensity Visual Analogue Scale (VAS)	Participants assessed pain intensity on a 100 mm visual analogue scale (VAS) with 0 meaning "no pain" and 100 meaning the "worst pain imaginable". The SPID VAS score for 0 to 48 hours following initial study drug dose measured the cumulative pain intensity difference during treatment with higher mean SPID VAS scores indicating greater improvement from Baseline. The SPID score is a measure of the cumulative pain intensity difference during treatment and the area under the curve was estimated using the linear trapezoidal rule.	From time of first study drug administration to 48 hours following first study drug administration	No
Secondary	TOTPAR (Total Pain Relief)	TOTPAR was the time-interval weighted sum of pain relief. Pain relief was assessed by participants' responses to how their pain relief was compared with the pain they had just before receiving the first dose of study drug: no relief, a little relief, some relief, a lot of relief, or complete relief. Higher mean TOTPAR scores indicate better pain relief. The TOTPAR score is a measure of the cumulative pain intensity difference during treatment and the area under the curve was estimated using the linear trapezoidal rule.	From time of first study drug administration to 48 hours following first study drug administration	No
Secondary	Participant's Global Assessment of Study Drug	The participant's overall impression of the study drug was obtained on a 5-point categorical scale: excellent; very good; good; fair; poor.	From time of first study drug administration to 48 hours following first study drug administration	No
Secondary	Time to Perceptible and Meaningful Pain Relief	The median time (minutes) from first perceptible pain relief (onset of pain relief) and time until first meaningful pain relief.	From time of first study drug administration to 12 hours following first study drug administration	No
Secondary	Participants With Adverse Events (AEs)	An adverse event (AE) is defined as any untoward medical occurrence in a participant, which does not necessarily have a causal relationship with treatment. If an adverse event meets any of the following criteria, it is considered a serious adverse event (SAE): results in death or is life-threatening, results in admission or prolongation of hospitalization, results in congenital anomaly or persistent or significant disability/incapacity, or is an important medical event requiring medical or surgical intervention to prevent serious outcome. AEs were categorized by severity (mild, moderate, severe) and relationship to treatment (probably, possibly, probably not, not related). Please see Adverse Events section below for more details.	AEs were recorded from study drug administration until 30 days following discontinuation of study drug (total 32 days); SAEs were recorded from the time informed consent was obtained until 30 days following discontinuation of study drug (total 51 days).	Yes
Secondary	Number of Participants With Vital Signs Values Meeting Potentially Clinically Significant Criteria	Potentially clinically significant criteria: Systolic blood pressure (BP) =90 mm Hg and =20 mm Hg decrease (low) or =180 mm Hg and =20 mm Hg increase (high); Diastolic BP =50 mm Hg and =15 mm Hg decrease (low) or =105 mm Hg and =15 mm Hg increase (high). Heart rate =50 beats per minute (bpm) and =15 bpm decrease (low) or =120 bpm and =15 bpm increase (high). Respiratory rate <10 respirations per minute (rpm) (low) or >24 rpm (high).	At specified intervals from Screening through 7 days after first dose of study drug	Yes
Secondary	Number of Participants With Chemistry Values Meeting Potentially Clinically Significant Criteria	Potentially clinically significant criteria: alanine aminotransferase/aspartate aminotransferase (ALT/AST) =3 times upper limit of normal (ULN); calcium =1.8 mmol/L.	At specified intervals from Screening through 7 days after first dose of study drug	Yes

External Links

•   Link